Shares of Alkermes PLC (ALKS) surged 5.07% in Thursday's trading session following the company's release of better-than-expected first-quarter 2025 financial results. The biopharmaceutical firm demonstrated resilience in a challenging market, beating both earnings and revenue estimates.

Alkermes reported quarterly adjusted earnings of $0.27 per share, surpassing the consensus estimate of $0.23 per share. While this represents a decrease from $0.43 per share in the same quarter last year, it still impressed investors by exceeding expectations. Revenue for the quarter came in at $306.51 million, topping analyst projections of $304.12 million, despite a 12.5% year-over-year decline.

The company's ability to outperform estimates in a tough economic environment, coupled with its reaffirmation of 2025 financial guidance, fueled investor optimism. Alkermes' CEO highlighted the firm's solid foundation and focus on executing strategic objectives to drive future value. The strong quarterly performance, particularly in the face of macroeconomic headwinds, has reinforced confidence in Alkermes' long-term prospects and management's ability to navigate challenges in the biopharmaceutical sector.